ORLANDO, FL, USA (UroToday.com) - Patrick Cotogno and colleagues from Tulane University sought to explore associations between abiraterone or enzalutamide progression, number of 223Ra cycles, prognostic factors, and overall survival (OS). Forty-two patients were treated with 223Ra. Ninety-four percent of patients without prior abiraterone or enzalutamide failure received ≥ 4 doses of 223Ra vs 60% of patients who did have progression on one of these drugs. Further, patients receiving ≥ 4 doses of 223Ra had a median OS of 303 days vs 89 days in those who received < 4 doses. PSA was predictably higher in patients who failed abiraterone or enzalutamide (208 versus 49 ng/mL).
These findings, although somewhat intuitive, have implications in terms of sequencing of agents as more and more become available for patients developing castration resistance and metastasis.
Presented by Patrick Cotogno, BS at the 2015 Genitourinary Cancers Symposium - "Integrating Biology Into Patient-Centric Care" - February 26 - 28, 2015 - Rosen Shingle Creek - Orlando, Florida USA
Tulane University, New Orleans, LA USA
Reported by Phillip Abbosh, MD, PhD, medical writer for UroToday.com